A Perspective on Potential Disease Modification in Atopic Dermatitis

Francisco Javier Melgosa Ramos has received honoraria and/or travel grants and/or has acted as an advisory board member for Novartis, AbbVie, Janssen Cilag, UCB, Lilly, LEO Pharma, L'Oreal, Sanofi, Almirall, and Amgen. Sergio Santos Alarcón has received honoraria and/or travel grants and/or has acted as an advisory board member for Almirall, AbbVie, Adium Pharma, Amgen, Pfizer, Novartis, Janssen-Cilag, Lilly, Leo Pharma, UCB Pharma, Pierre Fabre, Isdin, Sanofi, and Viñas. Juan Francisco Silvestre Salvador declares no conflicts of interest regarding the publication of this paper. Antonio Martorell has received honoraria and/or travel grants and/or has acted as an advisory board member for Novartis, AbbVie, Janssen Cilag, UCB, Lilly, LEO Pharma, L'Oreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squibb, and Amgen. He has also worked as a principal investigator in clinical trials supported by AbbVie, UCB, Janssen, Bristol Myers Squibb, Lilly, Galderma, Sanofi, and Novartis. Tiago Torres has received consultancy and/or speaker's honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA, and UCB. All data are available upon request from the authors.